ArticleJournal of gastroenterology2026

TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.

Hiroki Inada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.